Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

APOLLO-BC: Advanced Perfused platform for Breast Cancer therapy-response prediction

Objetivo

The limited ability of preclinical models to predict clinical responses remains a major barrier in oncology drug development. Current systems used for cancer drug evaluation, including conventional 2D cultures and advanced 3D models such as patient-derived organoids (PDOs), fail to control key tumour microenvironment (TME) parameters that influence drug penetration, adaptive resistance, and therapeutic response, potentially limiting predictive accuracy. Consequently, a gap persists between preclinical efficacy and clinical response, highlighting the need for ex vivo systems with improved predictive performance. Breast cancer provides a clinically relevant setting to address this challenge. Subtypes such as TNBC and HER2-positive disease show substantial variability in response to approved therapies, creating a need for improved methods to prioritise treatment options. APOLLO-BC tests whether controlling key tumour microenvironment parameters, specifically perfusion and mechanical stiffness, improves the predictive accuracy of therapy-response ranking compared with PDO systems. The project will generate the first controlled direct comparative validation of a perfused, stiffness-controlled tumour model against conventional PDO workflows using matched patient-derived samples. A microfluidic platform integrating bioprinted 3D tumour constructs and real-time environmental monitoring will be standardised, followed by generation of matched TNBC and HER2+ models and a benchmarking study across ≥40 patients, each tested with ≥6 approved therapeutic regimens. Reproducibility and predictive concordance with retrospective clinical outcomes will be quantitatively compared with PDO workflows.
By generating rigorous comparative evidence, APOLLO-BC will determine whether microenvironmental engineering improves predictive drug-response assessment in breast cancer models, establishing a validated framework for next-generation functional oncology platforms.

Ámbito científico (EuroSciVoc)

Este proyecto aún no se ha clasificado con EuroSciVoc.
Sugiera los ámbitos científicos que considere más relevantes y ayúdenos a mejorar nuestro servicio de clasificación.

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) ERC-2026-POC

Ver todos los proyectos financiados en el marco de esta convocatoria

Institución de acogida

FACULDADE DE CIENCIAS E TECNOLOGIADA UNIVERSIDADE NOVA DE LISBOA
Aportación neta de la UEn
€ 150 000,00
Coste total
Sin datos

Beneficiarios (1)